• PCV30 COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN IN GREEK PATIENTS WITH HYPERLIPIDAEMIA

    Nov 1, 2003, 00:00

  • PCV42 ECONOMIC ANALYSIS OF THE USE OF CONTRAST MEDIA DURING PERCUTANEOUS CORONARY INTERVENTION (PCI) IN FRANCE AND SPAIN

    Nov 1, 2003, 00:00

  • PHL12 MORE PRECISE DOSING INCREMENTS OF HUMAN GROWTH HORMONE DELIVERY SYSTEMS LEAD TO COST SAVINGS IN THE UK SETTING

    Nov 1, 2003, 00:00

  • PCV13 A SYSTEMATIC REVIEW AND META-ANALYSIS OF STUDIES COMPARING READMISSION RATES AND MORTALITY IN PATIENTS WITH HEART FAILURE

    Nov 1, 2003, 00:00

  • PMD44 ADVANCING RISK ADJUSTMENT FOR SCHIZOPHRENIA

    Nov 1, 2003, 00:00

  • CV4 IRBESARTAN IS PROJECTED TO BE COST AND LIFE SAVING IN THE FRENCH SETTING FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION, AND MICROALBUMINURIA

    Nov 1, 2003, 00:00

  • PHL3 COST-EFFECTIVENESS OF HAEMOPHILIA TREATMENT- A CROSS-NATIONAL ASSESSMENT

    Nov 1, 2003, 00:00

  • PGS6 COST EFFECTIVENESS OF CONTINUOUS AND ON-DEMAND THERAPY WITH ESOMEPRAZOLE 20MG IN PATIENTS WITH SYMPTOMATIC GASTROESOPHGEAL REFLUX DISEASE (GERD)- THE ONE STUDY

    Nov 1, 2003, 00:00

  • MH3 HOSPITALIZATION RELATED TO ABUSE OF THE ELDERLY WITH DEMENTIA AND OTHER MENTAL HEALTH DISORDERS- RESOURCE USE AND COSTS

    Nov 1, 2003, 00:00

  • PIN9 COST-EFFECTIVENESS OF TWO DIFFERENT VACCINATION STRATEGIES FOR THE PREVENTION OF MENINGOCOCCAL C DISEASE IN PORTUGAL

    Nov 1, 2003, 00:00

  • GD4 POTENTIAL HOSPITAL SAVINGS RELATED TO THE ADMINISTRATION OF ESOMEPRAZOLE TABLETS THROUGH GASTRIC TUBES IN PATIENTS CURRENTLY TREATED WITH INJECTABLE PPIS

    Nov 1, 2003, 00:00

  • PMH25 ASSESSING HEALTH-RELATED QUALITY OF LIFE IN CLINICAL TRIALS OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER

    Nov 1, 2003, 00:00

  • PCV22 ECONOMIC EVALUATION OF FONDAPARINUX COMPARED TO ENOXAPARIN IN VENOUS THROMBOEMBOLISM PREVENTION FOLLOWING HIP FRACTURE SURGERY

    Nov 1, 2003, 00:00

  • PCV40 ASSESSMENT OF THE COST OF CARDIOVASCULAR DEATH

    Nov 1, 2003, 00:00

  • PCV78 QUALITY OF LIFE IN CHRONIC PATHOLOGIES IN PRIMARY CARE

    Nov 1, 2003, 00:00

  • PGS7 COST ANALYSIS OF A NEW PROPOSAL FOR REIMBURSEMENT OF PROTON PUMP INHIBITOR TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) IN BELGIUM

    Nov 1, 2003, 00:00

  • PCV57 COST EFFECTIVENESS OF ANTIHYPERTENSIVE THERAPY IN DIABETIC PATIENTS IN ITALY

    Nov 1, 2003, 00:00

  • PMD33 THE USE OF A SEMI-MARKOV PROCESS MODEL IN COST-EFFECTIVENESS MODELING- THE CASE OF ANTI-EPILEPTIC DRUGS

    Nov 1, 2003, 00:00

  • PMD48 RELATIVE WEIGHTS ASSIGNED TO DRUGS AND BIOLOGICALS- OPPS METHODS AND CONCEPTS

    Nov 1, 2003, 00:00

  • PCV75 PROJECTED LIFE YEAR GAINED AND OTHER BENEFITS OF EZETIMIBE CO-ADMINISTRATION IN CHD PATIENTS NOT ATTAINING TOTAL CHOLESTEROL GOAL WITH STATIN MONOTHERAPY IN FINLAND

    Nov 1, 2003, 00:00

  • PAR4 ETANERCEPT VERSUS INFLIXIMAB PLUS METHOTREXATE IN RHEUMATOID ARTHRITIS- A COST-EFFECTIVENESS ANALYSIS FROM THE ITALIAN NHS PERSPECTIVE

    Nov 1, 2003, 00:00

  • PIN7 COSTS OF COMMUNITY-ACQUIRED PNEUMONIA FROM THE HOSPITALS PERSPECTIVE IN GERMANY-A PROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2003, 00:00

  • PMD6 DEVELOPMENT OF A WEB-BASED SURVEY TO DETERMINE PRACTICE PATTERNS FOR TREATMENT OF ADVANCED STAGE BREAST CANCER IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2003, 00:00

  • VV7 WILLINGNESS TO PAY FOR HEARING AIDS IN THE NETHERLANDS

    Nov 1, 2003, 00:00

  • PNM22 SOCIO-ECONOMIC IMPACT OF PARKINSONS DISEASE ON SPOUSES- THE COMPAS STUDY

    Nov 1, 2003, 00:00

  • PCV8 CHOICE OF FIRST-LINE TREATMENT FOR HYPERTENSION IN THE UK- DOES CURRENT PRIMARY CARE PRACTICE REFLECT BRITISH GUIDELINES?

    Nov 1, 2003, 00:00

  • QL2 OUALITY OF LIFE FOLLOWING AORTIC VALVE REPLACEMENT SURGERY

    Nov 1, 2003, 00:00

  • PAR3 EVALUATING THE IMPACT OF REIMBURSEMENT OF NON SELECTIVE COX2 INHIBITORS ON TOTAL DISPENSING OF SELECTED NSAID AND SELECTED DRUGS FOR ACID RELATED DISORDERS

    Nov 1, 2003, 00:00

  • PAE14 COST-EFFECTIVENESS ANALYSIS OF PMMA, SILICONE, AND ACRYLIC INTRA-OCULAR LENSES IN CATARACT THERAPY IN FOUR EUROPEAN COUNTRIES

    Nov 1, 2003, 00:00

  • PHP17 SURVEY ON DRUG VALUE ASSESSMENT AMONG PRESCRIBERS AND PAYERS IN ITALIAN HOSPITALS

    Nov 1, 2003, 00:00

  • CS3 INITIAL INSERTION OF A METAL STENT FOR PALLIATION OF MALIGNANT BILIARY OBSTRUCTION- A COST CONSEQUENCE ANALYSIS FOR ENGLAND, FRANCE AND SWEDEN

    Nov 1, 2003, 00:00

  • PMH11 PRODUCTION LOSSES IN BORDERLINE PERSONALITY DISORDER- SHORTCOMINGS IN THE STANDARD METHODS OF VALUATION

    Nov 1, 2003, 00:00

  • PCV16 EFFECTIVENESS AND COST-EFFECTIVENESS OF THE AMBULATORY BLOOD PRESSURE MONITORING (ABPM) IN THE DIAGNOSTIC OF HYPERTENSION

    Nov 1, 2003, 00:00

  • PRP14 COST OFFSETS FROM PRESCRIPTION COVERAGE OF AGED PERSONS WITH COPD

    Nov 1, 2003, 00:00

  • PIN32 THE POTENTIAL EPIDEMIOLOGICAL AND ECONOMIC IMPACT OF A NEW COMBINATION VACCINE AGAINST MENINGOCOCCAL B AND C AND PNEUMOCOCCAL INFECTIONS IN THE NETHERLANDS

    Nov 1, 2003, 00:00

  • PDB20 THE IMPACT OF DIABETES TYPE 2 ON QUALITY OF LIFE

    Nov 1, 2003, 00:00

  • PCV70 A PHARMACOECONOMIC COMPARISON OF UNFRACTIONATED HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN USAGE IN ACUTE CORONARY SYNDROME IN RUSSIA

    Nov 1, 2003, 00:00

  • PAE6 PREVALENCE AND BURDEN OF BLINDNESS AND LOW VISION IN SUBJECTS LIVING IN INSTITUTIONS- A NATION-WIDE SURVEY

    Nov 1, 2003, 00:00

  • PIN21 BUDGET IMPACT ANALYSIS OF UNIVERSAL VARICELLA VACCINATION IN GERMANY

    Nov 1, 2003, 00:00

  • PMD2 DISABILITY IN STROKE OUTCOMES RESEARCH- CLINICAL MEANING OF THE BARTHEL INDEX, THE FUNCTIONAL INDEPENDENCE MEASURE AND THE MODIFIED RANKIN SCALE

    Nov 1, 2003, 00:00

  • PHL11 DEVELOPMENT OF THE HAEMOPHILIA AGEGROUP SPECIFIC QUALITY OF LIFE QUESTIONNAIRE

    Nov 1, 2003, 00:00

  • PCN5 REPORT ON RETROSPECTIVE ANALYSIS OF HEALTH CARE COSTS OF BONE FRACTURES IN WOMEN WITH EARLY STAGE BREAST CANCER

    Nov 1, 2003, 00:00

  • PMH26 QUALITY OF LIFE IN SCHIZOPHRENIC PATIENTS IN SPAIN- ONE-YEAR FOLLOW-UP STUDY. SOHO STUDY

    Nov 1, 2003, 00:00

  • QL1 HEALTH-RELATED QUALITY OF LIFE IMPROVEMENTS IN AN EVIDENCE-BASED ASTHMA DISEASE MANAGEMENT PROGRAM

    Nov 1, 2003, 00:00

  • PMD21 LIFE EXPECTANCY AND THE DISCOUNTING OF HEALTH OUTCOMES

    Nov 1, 2003, 00:00

  • PMH17 HEALTH-RELATED QUALITY OF LIFE IN OUTPATIENTS WITH SCHIZOPHRENIA IN SINGAPORE

    Nov 1, 2003, 00:00

  • PCN7 ORAL VINORELBINE IN THE TREATMENT OF NON SMALL CELL LUNG CANCER

    Nov 1, 2003, 00:00

  • PHL1 HEMOGLOBIN LEVELS ASSOCIATED WITH DIAGNOSIS OF ANEMIA

    Nov 1, 2003, 00:00

  • PSN15 DURATION OF PSORIASIS AND QUALITY OF LIFE

    Nov 1, 2003, 00:00

  • PMH4 2-YEAR OUTCOMES OF RISPERDAL CONSTATM-THE FIRST ATYPICAL LONG ACTING INJECTABLE ANTIPSYCHOTIC- RESULTS FROM THE CANADIAN NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA

    Nov 1, 2003, 00:00

  • QL3 ECONOMIC AND QUALITY OF LIFE IMPACT OF SEASONAL ALLERGIC CONJUNCTIVITIS IN OXFORDSHIRE

    Nov 1, 2003, 00:00

  • RX1 PRESCRIPTION DRUG INFORMATION- A SURVEY OF THE GENERAL POPULATION IN SPAIN

    Nov 1, 2003, 00:00

  • PCV38 COST-EFFECTIVENESS OF TREATING BY SIMVASTATIN 40 MG/DAY HIGH VASCULAR RISK PATIENTS-AN ECONOMIC EVALUATION BASED ON THE HEART PROTECTION STUDY

    Nov 1, 2003, 00:00

  • PMD34 ANALYTIC CHOICES IN ECONOMIC MODELS OF TREATMENTS FOR RHEUMATOID ARTHRITIS- WHAT MAKES A DIFFERENCE?

    Nov 1, 2003, 00:00

  • PAR6 ACUTE GOUTY ARTHRITIS- THE COSTEFFECTIVENESS OF A NEW SELECTIVE COX-2 INHIBITOR (ETORICOXIB) IN THE UK

    Nov 1, 2003, 00:00

  • MS2 LISTENING TO OUR CONSUMERS- THE PHARMACEUTICAL BRAND LOYALIST

    Nov 1, 2003, 00:00

  • PDB9 THE COMPACT-STUDY- PIOGLITAZONE VS. INSULIN FOR TREATMENT OF PATIENTS WITH TYPE-2-DIABETES MELLITUS-A MEDICAL AND PHARMACOECONOMIC ANALYSIS

    Nov 1, 2003, 00:00

  • PRP9 INPATIENT MANAGEMENT OF ASTHMA IN CHILDREN AND ADOLESCENTS- HOSPITAL RESOURCE USE AND COSTS

    Nov 1, 2003, 00:00

  • PNM23 INTERNATIONAL USE OF HEALTH STATUS QUESTIONNAIRES IN PARKINSONS DISEASE- TRANSLATION IS NOT ENOUGH

    Nov 1, 2003, 00:00

  • PNM24 RIVASTIGMINE IS ASSOCIATED WITH SIGNIFICANTLY LESS CAREGIVER BURDEN THAN DONEPEZIL OR GALANTAMINE

    Nov 1, 2003, 00:00

  • HP1 A PROBLEM SHARED IS A PROBLEM HALVED? COST ACCEPTABILITY OF SHARED CARE VS HOSPITAL TREATMENT

    Nov 1, 2003, 00:00

  • VV5 ASTHMA TREATMENT PREFERENCE STUDY-A CONJOINT ANALYSIS OF PREFERRED DRUG TREATMENTS

    Nov 1, 2003, 00:00

  • PAR13 UTILITY VALUATION FROM THE PATIENT PERSPECTIVE OF TREATMENT OUTCOMES IN OSTEOARTHRITIS

    Nov 1, 2003, 00:00

  • PPN7 THE WILLINGNESS-TO-PAY APPROACH IN THE COST-BENEFIT ANALYSIS- THE TREATMENT OF PATIENTS AFFECTED FROM PAINFUL PATHOLOGY

    Nov 1, 2003, 00:00

  • PCV66 ONE BILLION EURO FOR THE TREATMENT WITH CSE-ANTAGONISTS IN GERMANY-WHAT ARE THE RESULTS?

    Nov 1, 2003, 00:00

  • PCN4 ANALYSIS ON COST DIFFERENCE BETWEEN DAILY FILGRASTIM AND ONCE PER CYCLE PEGFILGRASTIM FOR PROPHYLAXIS AGAINST CHEMOTHERAPY-INDUCED NEUTROPENIA IN FRANCE AND GERMANY

    Nov 1, 2003, 00:00

  • PRP2 HELIOX IN THE TREATMENT OF STATUS ASTHMATICUS IN THE ICU- A COSTEFFECTIVENESS ANALYSIS

    Nov 1, 2003, 00:00

  • PCV64 COST-EFFECTIVENESS ANALYSIS OF CORONARY REVASCULARISATION TECHNIQUES AVAILABLE FOR THE TREATMENT OF ISCHAEMIC HEART DISEASE

    Nov 1, 2003, 00:00

  • PRP8 THE COST-EFFECTIVENESS OF DIFFERENT INHALED COMBINATION THERAPIES IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ASTHMA-A MODELING STUDY FROM HEALTH CARE PAYER PERSPECTIVE IN POLAND

    Nov 1, 2003, 00:00

  • PCV23 ECONOMIC IMPACT OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION (ACS) UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI)- A EUROPEAN OVERVIEW

    Nov 1, 2003, 00:00

  • PUK11 SURVIVAL IN END-STAGE RENAL DISEASE (ESRD) PATIENTS- ECONOMIC CONSEQUENCES OF THE LACK OF AUTOLOGOUS ARTERIOVENOUS FISTULAE (AVF) AT THE START OF HEMODIALYSIS

    Nov 1, 2003, 00:00

  • PIN4 CONSUMPTION OF ANTIBIOTICS IN EUROPE- RESULTS OF THE ESAC RETROSPECTIVE DATA COLLECTION

    Nov 1, 2003, 00:00

  • PNM14 SOCIO-ECONOMIC IMPACT OF EPILEPSY ON PARENTS- THE TRILOGY STUDY

    Nov 1, 2003, 00:00

  • PNM18 COST-EFFECTIVENESS OF Z DRUGS (ZOLPIDEM, ZOPICLONE AND ZALEPLON) VERSUS BENZODIAZEPINES FOR THE SHORT-TERM MANAGEMENT OF INSOMNIA- A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2003, 00:00

  • MD4 STOCHASTIC ANALYSIS OF AN RANDOMIZED CONTROLLED TRIAL IN REHABILITATION OF LOW BACK PATIENTS- REPRESENTATION OF UNCERTAINTY WHEN EFFECT DIFFERENCE IS SMALL

    Nov 1, 2003, 00:00

  • PDB18 THE COMPLICATIONS IMPACT ON DIABETES TYPE 2 DIRECT COSTS IN POLAND

    Nov 1, 2003, 00:00

  • PHP10 HOSPITALIZATIONS FOR INJURIES RESULTING FROM CONTACT SPORTS- RESOURCE USE AND COSTS

    Nov 1, 2003, 00:00

  • PIN22 MODELLING THE COST-EFFECTIVENESS OF THE VARICELLA VACCINE IN PORTUGAL

    Nov 1, 2003, 00:00

  • PMD40 UTILISATION OF THE FOCUS GROUP TECHNIQUE IN THE DEVELOPMENT OF QUALITY OF LIFE QUESTIONNAIRES

    Nov 1, 2003, 00:00

  • PSN5 THE COST-UTILITY OF CALCIPOTRIOL/BETHAMETHASONE (DOVOBET) OINTMENT IN THE TREATMENT OF PSORIASIS VULGARIS IN THE UNITED KINGDOM

    Nov 1, 2003, 00:00

  • PCV21 THE COST OF STROKE IN SWEDEN-AN INCIDENCE ESTIMATE

    Nov 1, 2003, 00:00

  • PNM9 TIME SPENT AND COST ON INFORMAL CARE GIVING FOR PERSONS WITH ALZHEIMER IN SPAIN

    Nov 1, 2003, 00:00

  • PCV58 ECONOMIC IMPACT OF SELECTED FIXEDCOMBINATION ANGIOTENSIN-CONVERTING ENZYME INHIBITOR/CALCIUM CHANNEL BLOCKER ANTI-HYPERTENSIVES AMONG PATIENTS WITH DIABETES

    Nov 1, 2003, 00:00

  • PRP17 ESTIMATING HOSPITAL BURDEN DUE TO PNEUMONIA, ASPIRATION, AND ACUTE LUNG FAILURE- DATA FROM THE NATIONAL HOSPITAL DISCHARGE SURVEY (NHDS)

    Nov 1, 2003, 00:00

  • CP2 DETERMINANTS OF NON ADHERENCE TO ANTIHYPERTENSIVE DRUG TREATMENT

    Nov 1, 2003, 00:00

  • PSN7 TREATMENT OF PSORIASIS WITH CONVENTIONAL SYSTEMIC AGENTS IS ASSOCIATED WITH HIGH MEDICAL COSTS AND FREQUENT TREATMENT FAILURE

    Nov 1, 2003, 00:00

  • PSN13 COSTEFFECTIVENESS OF ALEFACEPT IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS

    Nov 1, 2003, 00:00

  • CP3 DISCONTINUATION RATES OF PHARMACOLOGICAL TREATMENTS FOR OVERACTIVE BLADDER- COMPARISON OF OXYBUTYNIN IMMEDIATE AND EXTENDED RELEASE IN THE UNITED KINGDOM

    Nov 1, 2003, 00:00

  • PMD28 CHALLENGES FOR MODEL-BASED ECONOMIC EVALUATIONS OF GLAUCOMA AND OCULAR HYPERTENSION TREATMENTS

    Nov 1, 2003, 00:00

  • PMD7 DATA ACQUISITION AND INTEGRATION FOR ANTIBIOTIC TREATMENT REPORTING

    Nov 1, 2003, 00:00

  • PGS10 COST OF ILLNESS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) IN ITALY

    Nov 1, 2003, 00:00

  • PHP21 IMPACT OF PHARMACY INTERVENTIONS ON QUALITY OF HOSPITAL PRESCRIBING- INTERVENTIONS AND COST SAVINGS ASSESSMENT

    Nov 1, 2003, 00:00

  • PMD8 PREDICTORS OF ANTIBIOTIC PRESCRIBING FOR UPPER RESPIRATORY INFECTIONS IN AN AMBULATORY POPULATION

    Nov 1, 2003, 00:00

  • PHP28 COST-BENEFIT ANALYSIS OF A STATE POISON CENTER

    Nov 1, 2003, 00:00

  • PMD12 COST SOURCE AND PERSPECTIVE IN ECONOMIC OUTCOMES STUDIES- FOCUS ON POSTERS PRESENTED AT THE 7TH ANNUAL INTERNATIONAL ISPOR MEETING

    Nov 1, 2003, 00:00

  • PCN18 THE COST OF GEMCITABINE/CISPLATIN COMPARED WITH FOUR OTHER NOVEL CHEMOTHERAPEUTIC AGENTS IN POLAND

    Nov 1, 2003, 00:00

  • PAR18 COST-EFFECTIVENESS ANALYSIS OF DIFFERENT DRUG THERAPIES FOR OSTEOPOROSIS

    Nov 1, 2003, 00:00

  • PSN9 PREVALENCE AND QUALITY OF LIFE OF PATIENTS SUFFERING FROM INFLAMMATORY DERMATITIS (PSORIASIS, ECZEMA, ATOPIC DERMATITIS AND URTICARIA) IN FRANCE-INSTANT STUDY

    Nov 1, 2003, 00:00

  • PHP33 EVALUATION AND SELECTION OF MEDICAL HEALTH TECHNOLOGIES- A GROUP DECISION SUPPORT SYSTEM (GDSS)

    Nov 1, 2003, 00:00

  • PNM20 VALIDATION OF SINGAPOREAN ENGLISH AND CHINESE EQ-5D VERSIONS IN PATIENTS WITH PARKINSONS DISEASE

    Nov 1, 2003, 00:00

  • PCV15 LOW GOAL ATTAINMENT IN COMMON DAILY PRACTICE AMONG PATIENTS WITH HYPERCHOLESTEROLEMIA IN THE NETHERLANDS-THE REALITY-PHARMO STUDY

    Nov 1, 2003, 00:00

  • PHL10 ASSESSING PATIENT PREFERENCES AND QUALITY-ADJUSTED LIFE YEARS (QALY) OF PROPHYLACTIC HAEMOPHILIA TREATMENT

    Nov 1, 2003, 00:00

  • PDB12 TYPE-2 DIABETES AND HOSPITAL COSTS ACCORDING TO OBESITY- A RETROSPECTIVE ANALYSIS FROM A HOSPITAL DATA BASE IN FRANCE

    Nov 1, 2003, 00:00

  • PMD42 LINGUISTIC VALIDATION OF THE QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE (Q-LES-Q) IN 24 LANGUAGES

    Nov 1, 2003, 00:00

  • PIN33 COST-EFFECTIVENESS OF DIFFERENT TREATMENT STRATEGIES WITH INTRAPARTUM ANTIBIOTIC PROPHYLAXIS TO PREVENT EARLY-ONSET GROUP B STREPTOCOCCAL DISEASE

    Nov 1, 2003, 00:00

  • PCV43 AN EVALUATION OF THE COSTS ASSOCIATED WITH ACUTE MI TREATMENT IN AND OUT OF HOSPITALS IN GREECE

    Nov 1, 2003, 00:00

  • PNM10 COST EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATELY SEVERE AND SEVERE ALZHEIMERS DISEASE IN SPAIN

    Nov 1, 2003, 00:00

  • PCV28 ECONOMIC EVALUATION AND SURVIVAL ANALYSIS OF IMMUNO-ADSORPTION IN PATIENTS WITH DILATED CARDIOMYOPATHY

    Nov 1, 2003, 00:00

  • CV6 AN ECONOMIC EVALUATION OF CLOPIDOGREL VS.ASPIRIN IN SECONDARY PREVENTION OF ISCHEMIC EVENTS IN HIGH RISK ATHEROTHROMBOTIC PATIENTS

    Nov 1, 2003, 00:00

  • MS4 THE IMPACT OF HEALTH CARE ATTITUDES ON PATIENT REPORTED OUTCOMES (PROS)

    Nov 1, 2003, 00:00

  • GD1 COST-UTILITY ANALYSIS OF RABEPRAZOLE AND ESOMEPRAZOLE FOR SYMPTOMATIC GASTRO OESOPHAGEAL REFLUX DISEASE

    Nov 1, 2003, 00:00

  • GL5 RESPONSIVENESS TO CHANGE OF THE SHORT FORM (SF)-12 HEALTH STATUS INSTRUMENT IN PATIENTS WITH CEREBROVASCULAR DISEASE

    Nov 1, 2003, 00:00

  • PAE16 PSYCHOMETRIC VALIDATION OF THE NEI-VFQ 25 FRENCH VERSION IN A POPULATION OF PATIENTS TREATED FOR OCULAR HYPERTENSION AND GLAUCOMA

    Nov 1, 2003, 00:00

  • PAE12 TREATMENT DURATION AS A COST DRIVER OF GLAUCOMA CARE- A LIFE-LONG SOCIETAL PERSPECTIVE IN FRANCE, GERMANY AND THE NETHERLAND

    Nov 1, 2003, 00:00

  • PMH9 THE SOCIO-ECONOMIC BURDEN OF BIPOLAR DISORDER IN THE NETHERLANDS

    Nov 1, 2003, 00:00

  • PSN14 QUALITY OF LIFE IN PATIENTS SUFFERING FROM PSORIASIS VULGARIS IN GERMANY-A NON-INTERVENTIONAL SURVEY

    Nov 1, 2003, 00:00

  • PDB21 A COST-UTILITY ANALYSIS OF INSULIN GLARGINE (LANTUS) IN THE TREATMENT OF PATIENTS WITH TYPE 1 DIABETES

    Nov 1, 2003, 00:00

  • PMD25 THE TIME INCONSISTENCY OF DECISIONS IN PHARMACOECONOMIC SEQUENTIAL DECISION PROBLEMS

    Nov 1, 2003, 00:00

  • PSN1 DERMATOLOGICAL DISEASES AND PODIATRIC DISORDERS IN THE FEET OF THE ELDERLY POPULATION-A DESCRIPTIVE STUDY

    Nov 1, 2003, 00:00

  • DB1 ACARBOSE FOR THE PREVENTION OF TYPE II DIABETES IN CANADA- AN ECONOMIC EVALUATION

    Nov 1, 2003, 00:00

  • PCV27 COST-EFFECTIVENESS ANALYSIS OF ANTITHROMBOTIC TREATMENT WITH CLOPIDOGREL IN PATIENTS WITH MYOCARDIAL INFARCTION, STROKE, AND PERIPHERAL ARTERIAL DISEASE IN THE NETHERLANDS

    Nov 1, 2003, 00:00

  • PMD24 FIRST EXPERIENCES WITH THE CONDUCTION OF RAPID HEALTH ECONOMIC HEALTH TECHNOLOGY ASSESSMENTS

    Nov 1, 2003, 00:00

  • PMD1 PROPERLY ADDRESSING TIME-DEPENDENCE WHEN ANALYZING THE IMPACT OF COMPLIANCE WITH MEDICATION IN CHRONIC ILLNESSES

    Nov 1, 2003, 00:00

  • MD2 THE PARAMETRIC BOOTSTRAP- RECONCILING PARAMETRIC AND NON PARAMETRIC METHODS IN THE ESTIMATION OF CONFIDENCE INTERVALS FOR INCREMENTAL COST-EFFECTIVENESS RATIOS?

    Nov 1, 2003, 00:00

  • PUK15 VALIDATION STUDY OF THE SPANISH VERSION OF THE ICIQ-SHORT FORM. A USEFUL INSTRUMENT IN DETECTING URINARY INCONTINENCE

    Nov 1, 2003, 00:00

  • PIN41 DEVELOPMENT OF THE HERPES OUTBREAK IMPACT QUESTIONNAIRE (HOIQ)

    Nov 1, 2003, 00:00

  • PHP2 AIDS AND ECONOMIC GROWTH- THE EPIDEMIC TRAP, THEORY AND CALIBRATION

    Nov 1, 2003, 00:00

  • PWH6 PATIENT AND PARTNER TREATMENT SATISFACTION SCALE (TSS) IN ERECTILE DYSFUNCTION

    Nov 1, 2003, 00:00

  • PNM27 FUNCTIONAL ASSESSMENT OF MULTIPLE SCLEROSIS (FAMS)- EVALUATING THE LINGUISTIC VALIDITY OF 5 NEW LANGUAGES- PORTUGUESE, JAPANESE, HEBREW, RUSSIAN, AND KOREAN

    Nov 1, 2003, 00:00

  • PCV25 THE COST AND THE MANAGEMENT OF THE ACUTE PHASE OF MYOCARDIAL INFARCTION AND STROKE IN HUNGARY

    Nov 1, 2003, 00:00

  • PCV44 PHARMACOECONOMIC EVALUATION OF VASOTEC IN HYPERTENSIVE PATIENTS WITH CONGESTIVE HEART FAILURE- AN UPDATE OF THE RETROSPECTIVE CANADIAN ANALYSIS BASED ON THE STUDIES OF LEFT VENTRICULAR DYSFUNCTION (SOLVD)

    Nov 1, 2003, 00:00

  • CE3 INTEGRATED ECONOMIC EVALUATION OF ENFUVIRTIDE (ENF) IN THE US USING A COMBINATION OF COST-EFFECTIVENES ANALYSIS (CEA) AND BUDGET IMPACT ANALYSIS (BIA) TO ENHANCE HEALTH CARE DECISION-MAKING

    Nov 1, 2003, 00:00

  • PCV49 COST-EFFECTIVENESS ANALYSIS OF CITICOLINE VS CONVENTIONAL TREATMENT IN STROKE PATIENTS

    Nov 1, 2003, 00:00

  • CV12 A COST-EFFECTIVENESS ANALYSIS OF ACE INHIBITOR TRANDOLAPRIL AS A PREVENTATIVE TREATMENT OF HEART-FAILURE PROGRESSION

    Nov 1, 2003, 00:00

  • ME3 ESTIMATING COST-EFFECTIVENESS IN THE ABSENCE OF HEAD-TO-HEAD CLINICAL TRIALS-EXAMPLES OF TWO RECENT TECHNOLOGY ASSESSMENTS FOR NICE

    Nov 1, 2003, 00:00

  • PNM8 ALZHEIMERS DISEASE COST OF TREATMENT STUDY (ADCOT) IN THE UNITED KINGDOM

    Nov 1, 2003, 00:00

  • PHP5 HOW PHARMACOECONOMICS INDICATORS FOR THERAPEUTIC INNOVATIONS IN ACUTE AND CHRONIC DISEASE CAN ASSIST PAYORS IN THE DECISION MAKING PROCESS

    Nov 1, 2003, 00:00

  • GD3 COSTS OF GASTROENTERITIS IN THE NETHERLANDS

    Nov 1, 2003, 00:00

  • PIN42 MEASURING TREATMENT-SPECIFIC ASPECTS OF HRQL IN PATIENTS SUFFERING FROM PRIMARY ANTIBODY DEFICIENCIES

    Nov 1, 2003, 00:00

  • PSN16 PSORIASIS- IMPACT OF THE TREATMENT ON QUALITY OF LIFE

    Nov 1, 2003, 00:00

  • PNM26 STANDARD GAMBLE TECHNIQUE-A TOOL TO ASSESS QUALITY OF LIFE IN PATIENTS WITH EPILEPSY

    Nov 1, 2003, 00:00

  • PCV50 COSTS OF THE DIAGNOSIS OF RENAL ARTERY STENOSIS

    Nov 1, 2003, 00:00

  • PCV72 COST-EFFECTIVENESS OF ATORVASTATIN COMPARED TO SIMVASTATIN IN THE NETHERLANDS

    Nov 1, 2003, 00:00

  • DB3 COST-EFFECTIVENESS OF ROSIGLITAZONE-METFORMIN COMBINATION IN OVERWEIGHT PATIENTS WITH TYPE 2 DIABETES IN GERMANY

    Nov 1, 2003, 00:00

  • CV2 THE ECONOMIC BURDEN OF STROKE IN SPAIN

    Nov 1, 2003, 00:00

  • PDB17 PREDICTED COSTS AND OUTCOMES FROM REDUCED VIBRATION DETECTION IN PEOPLE WITH DIABETES IN THE UK

    Nov 1, 2003, 00:00

  • PCV48 LONG-TERM COST-EFFECTIVENESS OF INVASIVE STRATEGY IN PATIENT WITH UNSTABLE CORONARY ARTERY DISEASE-RESULTS FROM THE FRISC-II TRIAL

    Nov 1, 2003, 00:00

  • PCV29 USE OF RESOURCES AND COST IMPLICATIONS OF STROKE PROPHYLAXIS WITH WARFARIN FOR PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

    Nov 1, 2003, 00:00

  • Disclosure Information

    Nov 1, 2003, 00:00

  • PCN15 COST ANALYSIS OF TREATMENT FOR ADVANCED OR RECURRENT GASTRIC CANCER IN JAPAN- ECONOMIC COMPARISON BETWEEN THE ORAL FLUOROPYRIMIDINE TS-1 AND CONVENTIONAL INTRAVENOUS CHEMOTHERAPY

    Nov 1, 2003, 00:00

  • PCN20 PEGFILGRASTIM IS PREFERRED TO FILGRASTIM IN CANCER PATIENTS ON MYELOSUPPRESSIVE CHEMOTHERAPY TREATMENT REGIMENS

    Nov 1, 2003, 00:00

  • PDB5 EVIDENCE-BASED ASSESSMENT OF PATIENTS RISK AND POTENTIAL REGARDING THE LONGTERM COMPLICATIONS OF DIABETES USING A NEW MODEL OF PROGNOSIS IN THE DM PROJECT DIAMART

    Nov 1, 2003, 00:00

  • Author Index, Volume 6

    Nov 1, 2003, 00:00

  • PIN3 ASSOCIATION BETWEEN SKIN TATOOS AND HEPATITIS B OF 1/2000 PRIVATES AT ADISORN FORT HOSPITAL, THAIALND

    Nov 1, 2003, 00:00

  • PWH7 A NEW INSTRUMENT TO MEASURE THE PSYCHOLOGICAL IMPACT OF ERECTILE DYSFUNCTION. VALIDATION OF A SPANISH VERSION OF THE JOHNSON AND MCCOYS SELF-CONFIDENCE SCALE

    Nov 1, 2003, 00:00

  • PMH6 PHARMACOUTILIZATION OF ANTIDEPRESSANT DRUGS IN PRIMARY CARE- A LONG-TERM RETROSPECTIVE ANALYSIS OF A LARGE POPULATION

    Nov 1, 2003, 00:00

  • VV3 HOW STABLE ARE SOCIAL PREFERENCE WEIGHTS FOR EQ-5D- RESULTS FROM A PA RTIAL REPLICATION STUDY

    Nov 1, 2003, 00:00

  • PHL9 APPLICATION OF CONJOINT ANALYSIS TO ELICIT PREFERENCES IN HEMOPHILIA CARE- THE CONAN STUDY GROUP

    Nov 1, 2003, 00:00

  • PGS12 IMPACT ON WORK PRODUCTIVITY OF UPPER GASTROINTESTINAL SYMPTOMS ASSOCIATED WITH CHRONIC NSAID THERAPY IN A SWEDISH STUDY POPULATION

    Nov 1, 2003, 00:00

  • PCV12 EFFECT OF EPROSARTAN ON PULSE PRESSURE PREDICTIVE FACTORS OF RESPONSE

    Nov 1, 2003, 00:00

  • PGS9 A COST CONSEQUENCE ANALYSIS OF A NEW ENDOSCOPIC INJECTABLE TREATMENT VERSUS SURGERY IN PATIENTS WITH SEVERE GASTRO ESOPHAGEAL REFLUX DISEASE IN FRANCE

    Nov 1, 2003, 00:00

  • PNM19 RESOURCE UTILISATION AND COSTS OF PATIENTS WITH SPINAL CORD INJURY (SCI) AFTER INITIAL REHABILITATION

    Nov 1, 2003, 00:00

  • PCV56 ESTABLISHING THE COST-EFFECTIVENESS OF STATINS IN THE PRIMARY PREVENTION OF CHD USING A QUASI MARKOV MODEL

    Nov 1, 2003, 00:00

  • PMD16 UNCERTAINTY AND VALUE OF INFORMATION IN RAPID ECONOMIC EVALUATIONS

    Nov 1, 2003, 00:00

  • PMD43 BENEFITS OF TRANSLATABILITY ASSESSMENT TO ENHANCE THE COHERENCE OF DATA IN INTERNATIONAL STUDIES-THE IQOD EXPERIENCE

    Nov 1, 2003, 00:00

  • CV10 COST-EFFECTIVENESS OF LOVASTATIN, CHOLESTYRAMINE AND GEMFIBROZIL FOR THE PRIMARY PREVENTION OF CORONARY HEART DISEASE THROUGH CHOLESTEROL REDUCTION IN CATALONIA, SPAIN

    Nov 1, 2003, 00:00

  • PPN1 TOPIRAMATE FOR THE TREATMENT OF PERIPHERAL DIABETIC NEUROPATHY- CANADIAN CLINICAL EXPERIENCE

    Nov 1, 2003, 00:00

  • PCV76 IS THE MLHF QUESTIONNAIRE VALID FOR INTERNATIONAL MULTICENTRIC STUDIES?

    Nov 1, 2003, 00:00

  • PGS2 A RETROSPECTIVE AUDIT OF PATIENTS REDUCING PROTON PUMP INHIBITOR DOSE TO LANSOPRAZOLE 15MG

    Nov 1, 2003, 00:00

  • PCN10 COSTS OF MANAGING TOXICITIES IN ADVANCED NON-SMALL CELL LUNG CANCER WITH PEMETREXED COMPARED WITH DOCETAXEL AS SECOND-LINE CHEMOTHERAPY

    Nov 1, 2003, 00:00

  • PAR8 AVERAGE DAILY DOSE AND COSTS OF REIMBURSED COX-2 INHIBITORS FOR PATIENTS WITH RHEUMATOID ARTHRITIS IN NORWAY

    Nov 1, 2003, 00:00

  • PRP7 A CROSS-SECTIONAL, OBSERVATIONAL STUDY TO ESTABLISH THE RESOURCES AND COSTS ASSOCIATED WITH CONTROLLED AND POORLY CONTROLLED MODERATE TO SEVERE ASTHMA PATIENTS IN THE UK

    Nov 1, 2003, 00:00

  • PCV20 ECONOMIC MODELLING OF ANTIPLATELET THERAPY IN THE PREVENTION OF RECURRENT STROKE

    Nov 1, 2003, 00:00

  • PIN34 COST-EFFECTIVENESS OF TWO SCREENING STRATEGIES FOR CHLAMYDIA TRACHOMATIS INFECTIONS IN FRANCE

    Nov 1, 2003, 00:00

  • PHP22 AN INVESTIGATION OF GENERIC DRUG UTILISATION AND POTENTIAL SAVINGS FROM GENERIC SUBSTITUTION IN THE IRISH HEALTH CARE SETTING

    Nov 1, 2003, 00:00

  • PGS8 COST-MINIMISATION ANALYSIS OF PPI-BASED TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER PYLORI

    Nov 1, 2003, 00:00

  • PHP24 THE VALUE OF BOARD OF PHARMACEUTICAL SPECIALTY CERTIFICATION- RESOURCE USE AND DECISION-MAKING

    Nov 1, 2003, 00:00

  • PRP1 EPIDEMIOLOGY OF NASAL POLYPS AND ITS RELATIONSHIP TO ASTHMA

    Nov 1, 2003, 00:00

  • PHP36 A MULTIDIMENSIONAL HEALTH CARE INTERVENTION APPRAISAL- THE COORDINATED PALLIATIVE CARE NETWORK 'QUIETUDE'

    Nov 1, 2003, 00:00

  • PCV36 COST-EFFECTIVENESS OF EARLY THROMBOLYSIS FOR THE TREATMENT OF ACUTE MYOCARDIAL INFARCTION- A SYSTEMATIC REVIEW OF THE LITERATURE

    Nov 1, 2003, 00:00

  • PIN16 COST-EFFECTIVENESS ANALYSIS OF FUZEON ADDED TO OPTIMAL STANDARD THERAPY VS. OPTIMIZED BACKGROUND REGIMEN ALONE IN PATIENTS WITH HIV/AIDS

    Nov 1, 2003, 00:00

  • PMD46 PROCESS UTILITY DERIVED FROM PROVIDING INFORMAL CARE

    Nov 1, 2003, 00:00

  • PMD47 CALCULATING UTILITY VALUES FROM SF-36- A COMPARISON OF DIFFERENT ALGORITHMS

    Nov 1, 2003, 00:00

  • PCV54 ECONOMIC EVALUATION OF ROSUVASTATIN IN A NATURALISTIC SETTING

    Nov 1, 2003, 00:00

  • PCV9 THE USE OF SHORT MESSAGES TO THE PATIENTS MOBILE PHONE AS HEALTH CARE TOOL IN HYPERTENSION- THE HTA-ALERT STUDY AND THE INFONET PROGRAM

    Nov 1, 2003, 00:00

  • PNM17 RETROSPECTIVE EVALUATION OF THE DOSE OF DYSPORT AND BOTOX IN THE CLINICAL MANAGEMENT OF CERVICAL DYSTONIA OR BLEPHAROSPASM-COST CONSIDERATIONS FOR THE REAL DOSE STUDY

    Nov 1, 2003, 00:00

  • PCV47 A COST-EFFECTIVENESS ANALYSIS OF TAXUSTM DRUG-ELUTING STENT IN THE UK

    Nov 1, 2003, 00:00

  • PHP20 MARKET SHARE AND CHARACTERISTICS OF GENERIC DRUGS IN GREECE

    Nov 1, 2003, 00:00

  • RX4 PATTERNS OF USE OF COXIBS AND NON-SELECTIVE NSAIDS IN THE ELDERLY POPULATION OF QUEBEC (CANADA)

    Nov 1, 2003, 00:00

  • PNM3 A COST EFFECTIVENESS ANALYSIS OF ZOLMITRIPTAN NASAL SPRAY

    Nov 1, 2003, 00:00

  • HP4 CHILDHOOD VACCINATION AGAINST VARICELLA IN FRANCE- AN ECONOMIC EVALUATION OF DIFFERENT STRATEGIES

    Nov 1, 2003, 00:00

  • PUK2 TREATMENT PERSISTENCE OF OXYBUTYNIN XL AND TOLTERODINE IR IN A REAL-WORLD CLINICAL PRACTICE SETTING- DATA FROM THE UNITED KINGDOM

    Nov 1, 2003, 00:00

  • PHP34 THE EFFECTS OF GENETIC TESTING ON THE DEMAND FOR LIFE INSURANCE

    Nov 1, 2003, 00:00

  • PGS11 USING A COST-UTILITY ANALYSIS FOR ASSESSING SENSITIVITY IN DRUG PRICES OF ESOMEPRAZOLE VERSUS OMEPRAZOLE IN THE ACUTE TREATMENT OF REFLUX OESOPHAGITIS IN THE UK

    Nov 1, 2003, 00:00

  • PIN29 REDUCING INFLUENZA SYMPTOMS BY 1.5 DAYSA PROSPECTIVE RANDOMIZED TRIAL USING THE CONTINGENT VALUATION METHOD TO ELICIT PREFERENCES FOR NEURAMINIDASE INHIBITORS

    Nov 1, 2003, 00:00

  • PMD17 PROTOCOL FOR MEDICOECONOMIC EVALUATION OF OUTPATIENT MANAGEMENT OF INFANTILE BRONCHIOLITIS

    Nov 1, 2003, 00:00

  • PCV62 CLINICAL AND ECONOMIC OUTCOMES OF FONDAPARINUX VS. ENOXAPARIN IN THE PROPHYLAXIS OF VENOUS THROMBOEMBOLISM AFTER MAJOR ORTHOPAEDIC SURGERY IN SPAIN

    Nov 1, 2003, 00:00

  • PAR17 COST-EFFECTIVENESS OF QUANTITATIVE ULTRASOUND AS A TECHNIQUE FOR SCREENING AND DIAGNOSING OSTEOPOROSIS AND SUBSEQUENTLY FOR THE PREVENTION OF OSTEOPOROTIC FRACTURES

    Nov 1, 2003, 00:00

  • PHP32 MANAGING TECHNOLOGICAL INNOVATION IN THE HEALTH CARE SECTOR

    Nov 1, 2003, 00:00

  • PUK8 SEVELAMER USE IN HYPERPHOSPHATEMIA- HEALTH AND ECONOMIC CONSEQUENCES

    Nov 1, 2003, 00:00

  • DB4 TYPE OF DIABETES AND ADHERENCE TO SELF-MONITORING OF BLOOD GLUCOSE (SMBG)

    Nov 1, 2003, 00:00

  • PCN14 COST IMPLICATIONS OF ORAL TREATMENT OF COLORECTAL CANCER IN GERMANY

    Nov 1, 2003, 00:00

  • PMH18 ZIPRASIDONE VS OLANZAPINE- CHANGE IN CHD RISK DURING A SIX-WEEK TRIAL

    Nov 1, 2003, 00:00

  • MD1 A TALE OF TWO STUDIES-A COMPARISON OF ECONOMIC DATA FROM A CLINICAL TRIAL TO A CROSS-SECTIONAL DATABASE

    Nov 1, 2003, 00:00

  • PAR16 AN ASSESSMENT OF THE ECONOMIC BURDEN OF BENZODIAZEPINE-ASSOCIATED HOSPITAL TREATED FALL INJURIES IN THE EUROPEAN UNION

    Nov 1, 2003, 00:00

  • PAE4 CONSTRUCT VALIDITY AND RELIABILITY OF THE EYE ALLERGY PATIENT IMPACT QUESTIONNAIRE (EAPIQ)

    Nov 1, 2003, 00:00

  • PWH8 DEVELOPMENT AND INITIAL TESTING OF A NEW PATIENT-REPORTED QUESTIONNAIREERECTION QUALITY SCALE

    Nov 1, 2003, 00:00

  • PIN10 A COST CONSEQUENCE ON CONCOMITANT DRUG USE DURING HCV THERAPY IN MANAGED CARE PATIENTS IN THE UNITED STATES

    Nov 1, 2003, 00:00

  • PNM25 DRUG PERSISTENCE PATTERNS SIMILAR FOR RIVASTIGMINE-TREATED PATIENTS AND DONEPEZIL-TREATED PATIENTS

    Nov 1, 2003, 00:00

  • PWH1 EFFECT OF ORAL LOW-DOSE HORMONAL REPLACEMENT THERAPY (COMBINED ESTRADIOL 1MG AND NORESTISTERONE ACETATE 0.5MG) ON CARDIOVASCULAR RISK IN SPANISH POSTMENOPAUSAL WOMEN

    Nov 1, 2003, 00:00

  • PSN10 THE USE OF DISCRETE CHOICE ANALYSIS TO ASSIST WITH THE INTERPRETATION OF QUALITY OF LIFE SCORES

    Nov 1, 2003, 00:00

  • PCV34 COST-EFFECTIVENESS OF FRACTIONAL FLOW RESERVE TESTING TO GUIDE PERCUTANEOUS CORONARY INTERVENTION IN THE DRUG-ELUTING STENT ERA- A DECISION ANALYSIS

    Nov 1, 2003, 00:00

  • PHP30 THE IMPLICATIONS OF THE USE OF TUBE FEEDING IN THE UK SECONDARY HEALTH CARE SYSTEM

    Nov 1, 2003, 00:00

  • PHP31 PAYMENTS FOR HIGH COST NEW TECHNOLOGY DRUGS AND BIOLOGICALS IN THE HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM- POLICY IMPLICATIONS

    Nov 1, 2003, 00:00

  • PHP37 USING PATIENT REPORTED OUTCOMES (PRO) DATA TO SEGMENT HEALTH CARE CONSUMERS AND UNCOVER THEIR RECEPTIVENESS TO PHARMACEUTICAL ADVERTISING

    Nov 1, 2003, 00:00

  • PHP35 SMOKING CESSATION- RELEVANCE IN THE UNDER 25 GROUP

    Nov 1, 2003, 00:00

  • PUK3 TREATMENTS RECEIVED FOR STRESS URINARY INCONTINENCE (SUI) SYMPTOMS BY PATIENTS SEEKING HELP WITHIN A UK PRIMARY CARE SETTING

    Nov 1, 2003, 00:00

  • PIN40 PREVALENCE AND QUALITY OF LIFE OF PATIENTS SUFFERING FROM HERPES LABIALIS WITH IN FRANCE-INSTANT STUDY

    Nov 1, 2003, 00:00

  • PMD5 A METHOD FOR IDENTIFICATION OF FRONTIER PRACTICE IN DIABETES CARE

    Nov 1, 2003, 00:00

  • PIN12 THE COST-EFFECTIVENESS ANALYSIS OF PEGINTERFERON ALFA-2A AND RIBAVIRIN VERSUS INTERFERON ALFA-2B AND RIBAVIRIN IN CHRONIC HEPATITIS C IN POLAND

    Nov 1, 2003, 00:00

  • PDB11 THE ECONOMIC CONSEQUENCES OF DIABETES TYPE 2 IN POLAND

    Nov 1, 2003, 00:00

  • PDB10 DIABETES DISEASE MANAGEMENT IS ASSOCIATED WITH PHARMACY SAVINGS IN A MANAGED CARE SETTING

    Nov 1, 2003, 00:00

  • PCN13 COST-EFFECTIVENESS OF MOHSMICROGRAPHIC SURGERY VERSUS SURGICAL EXCISION FOR THE TREATMENT OF FACIAL BASAL CELL CARCINOMAS- RESULTS OF A RANDOMISED CLINICAL TRIAL

    Nov 1, 2003, 00:00

  • ME2 A USER-FRIENDLY TOOL FOR EVALUATING AND IMPROVING THE TRANSFERABILITY OF ECONOMIC EVALUATION RESULTS BETWEEN COUNTRIES

    Nov 1, 2003, 00:00

  • MD3 THE IMPLICATIONS OF COMBINING HETEROGENEOUS PATIENT POPULATIONS IN META-ANALYSES

    Nov 1, 2003, 00:00

  • CS2 BURDEN OF ILLNESS OF INFLUENZA

    Nov 1, 2003, 00:00

  • PHP11 EFFECT OF COPAY INCREASE ON COMPLIANCE- A NATURAL EXPERIMENT

    Nov 1, 2003, 00:00

  • PMH2 EVALUATION OF ANTIDEPRESSANT MEDICATION ADHERENCE IN A NOT FOR PROFIT HEALTH CARE ORGANIZATION

    Nov 1, 2003, 00:00

  • PMH19 CLIENT AND STAFF INVOLVEMENT IN FORMAT DESIGN OF A HEALTH-RELATED QUALITY OF LIFE SURVEY FOR INDIVIDUALS WITH SCHIZOPHRENIA, THE SCHIZOPHRENIA OUTCOMES ASSESSMENT PROJECT (SOAP) SURVEY

    Nov 1, 2003, 00:00

  • PCV74 MEASURING HEALTH RELATED QUALITY OF LIFE AFTER STROKE

    Nov 1, 2003, 00:00

  • PMD45 OUTCOMES RESEARCH AND PHASE 1-2 PHARMACEUTICAL RISK ASSESSMENT

    Nov 1, 2003, 00:00

  • PUK13 COMPARISON OF THE PERFORMANCE AND DATA QUALITY OF ELECTRONIC AND PAPER DIARIES FOR BENIGN PROSTATIC HYPERPLASIA (BPH)

    Nov 1, 2003, 00:00

  • PIN24 THE COST-EFFECTIVENESS OF 23-VALENT PNEUMOCOCCAL VACCINE IN CATALONIA, SPAIN

    Nov 1, 2003, 00:00

  • PMD20 THE COST-EFFECTIVENESS OF SCREENING PROGRAMS USING SINGLE AND MULTIPLE BIRTH COHORT SIMULATIONS- A COMPARISON USING A MODEL OF CERVICAL CANCER

    Nov 1, 2003, 00:00

  • PMH23 DEVELOPMENT AND ASSESSMENT OF HEALTH STATE UTILITIES FOR ATTENTION DEFICIT/HYPERACTIVITY DISORDER IN CHILDREN USING PARENT PROXY REPORT

    Nov 1, 2003, 00:00

  • PNM1 CARE OF PARKINSONS DISEASE (EUROPA)

    Nov 1, 2003, 00:00

  • PHP13 POLICIES FOR INCLUSION OF DRUGS FOR REIMBURSEMENT BY THE PHILIPPINE HEALTH INSURANCE CORPORATION

    Nov 1, 2003, 00:00

  • PNM6 INDIRECT COSTS DUE TO MIGRAINE IN THE UNITED STATES

    Nov 1, 2003, 00:00

  • PMH15 COST-EFFECTIVENESS ANALYSIS OF LONG-ACTING RISPERIDONE (LA-RIS) VS HALOPERIDOL DECANOATE AND ORAL OLANZAPINE IN THE TREATMENT OF SCHIZOPHRENIA IN ITALY

    Nov 1, 2003, 00:00

  • PMD38 WORST AND BEST EYE VISUAL ACUITY CONSEQUENCES ON VISION-RELATED QUALITY OF LIFE IN PATIENTS SUFFERING FROM AGE RELATED MACULAR DEGENERATION

    Nov 1, 2003, 00:00

  • PCV17 COST-EFFECTIVENESS ANALYSIS OF DALTEPARIN IN PROLONGED PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS AFTER HIP ARTHROPLASTY

    Nov 1, 2003, 00:00

  • PIN23 SPANISH HEALTH INTERVENTIONS FOR CHRONIC HEPATITIS B AND THEIR ASSOCIATED COSTS

    Nov 1, 2003, 00:00

  • PAR1 TREATMENT ADHERENCE WITH TNFINHIBITORS AND METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS IN A LARGE STATE MEDICAID PROGRAM

    Nov 1, 2003, 00:00

  • PHP27 THE ASSOCIATION OF RECOMMENDED SURGICAL SITE INFECTION GUIDELINES AND OTHER FACTORS WITH HOSPITAL LENGTH OF STAY (LOS) IN PATIENTS UNDERGOING DIFFERENT CLEAN OR CLEANCONTAMINATED PROCEDURES

    Nov 1, 2003, 00:00

  • PAR9 PATTERNS OF USE, DOSING AND ECONOMIC IMPACT OF BIOLOGIC AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS

    Nov 1, 2003, 00:00

  • PPN8 SUSTAINED-RELEASE TRAMADOL IN CHRONIC PAIN TREATMENT- EFFECTIVENESS AND INFLUENCE ON QUALITY OF LIFE

    Nov 1, 2003, 00:00

  • PIN25 COST-EFFECTIVENESS OF A PHARMACY-BASED SCREENING FOR CHLAMYDIA TRACHOMATIS

    Nov 1, 2003, 00:00

  • PMD22 EPIDEMIOLOGY AND PHARMAECONOMY OF COPD ACROSS EUROPE

    Nov 1, 2003, 00:00

  • PHP6 RESEARCH 5539- COMPARISON OF ACTUAL COSTS AND DRG-BASED REIMBURSEMENT OF INTENSIVE CARE IN GERMAN ICUS

    Nov 1, 2003, 00:00

  • PNM11 IMPACT OF DEEP BRAIN STIMULATION (DBS) OF THE SUBTHALAMIC NUCLEUS (STN) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND HEALTH CARE RESOURCE USE IN ADVANCED PARKINSONIAN PATIENTS

    Nov 1, 2003, 00:00

  • PHP19 CONSUMER VALUATION OF PRESCRIPTION DRUG BENEFIT PLANS

    Nov 1, 2003, 00:00

  • PWH5 QUALITY OF LIFE (QOL) DIFFERENTIATION ANALYSIS IN PATIENTS UNDERGOING CONTROLLED OVARIAN STIMULATION (COS) WITH TWO DIFFERENT PREPARATIONS OF RECOMBINANT HUMAN FOLLICLESTIMULATING HORMONE (R-HFSH)

    Nov 1, 2003, 00:00

  • PCV41 A COST ANALYSIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES USING CLOPIDOGREL IN ADDITION TO ASPIRIN IN A HONG KONG PUBLIC HOSPITAL

    Nov 1, 2003, 00:00

  • PAE17 ASSESSING THE VALUE OF LASER IN SITU KERATOMILEUSIS (LASIK) BY PATIENT REPORTED OUTCOMES

    Nov 1, 2003, 00:00

  • PIN38 COST-EFFECTIVENESS ANALYSIS OF PEGYLATED INTERFERONS COMBINED WITH RIBAVIRIN IN THE TREATMENT OF HEPATITIS C

    Nov 1, 2003, 00:00

  • PMH16 AN ECONOMIC EVALUATION OF ARIPIPRAZOLE VERSUS OLANZAPINE IN A SWEDISH SETTING USING OUTCOMES OF METABOLIC SYNDROME, PROJECTED DIABETES AND CORONARY HEART DISEASE

    Nov 1, 2003, 00:00

  • PPN9 CHRONIC PAIN PATIENTS SATISFACTION AND QUALITY OF LIFE WITH TRANSDERMAL ANALGESIC MEDICATION

    Nov 1, 2003, 00:00

  • PMD41 THE NATURE OF THE QUALITY-ADJUSTED LIFE YEAR (QALY) CALCULATION

    Nov 1, 2003, 00:00

  • PHP8 THE EUROPEAN NETWORK OF HEALTH ECONOMIC EVALUATION DATABASES (EURO NHEED) PROJECT

    Nov 1, 2003, 00:00

  • PAR2 TOWARDS VALUING PREFERENCES FOR DISTRIBUTION OF HEALTH GAIN IN HIP AND KNEE DISEASE

    Nov 1, 2003, 00:00

  • PCV69 THE COST-EFFECTIVENESS OF CYP2C9 GENOTYPING IN MANAGEMENT OF WARFARIN THERAPY-A DECISION TREE ANAYSIS

    Nov 1, 2003, 00:00

  • DB2 PIOGLITAZONE MONOTHERAPY IS ASSOCIATED WITH A SIGNIFICANTLY LOWER INCIDENCE OF CARDIOVASCULAR EVENTS THAN IS INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES- A RETROSPECTIVE PROPENSITY-ADJUSTED COHORT ANALYSIS

    Nov 1, 2003, 00:00

  • PIN18 PROJECTED CLINICAL BENEFITS AND COSTEFFECTIVENESS OF AN HPV 16/18 VACCINE

    Nov 1, 2003, 00:00

  • PNM16 THE COSTS OF MULTIPLE SCLEROSIS-A CROSS-SECTIONAL PROSPECTIVE MULTICENTRE COST OF ILLNESS STUDY IN POLAND

    Nov 1, 2003, 00:00

  • PHL4 COST OF CARE AND QUALITY OF LIFE IN HEMOPHILIACS DEVELOPING INHIBITORS AGAINST PRODUCTS OF COAGULATION- THE COCIS STUDY

    Nov 1, 2003, 00:00

  • PCV73 DEVELOPMENT OF PATIENT-REPORTED OUTCOME MEASURES FOR PULMONARY ARTERIAL HYPERTENSION

    Nov 1, 2003, 00:00

  • PHP16 SPANISH NATIONAL HEALTH SERVICE- ANALYSIS OF THE INTRODUCTION OF NEW DRUGS IN THE CLINICAL PRACTICE FROM 1996 TO 2000

    Nov 1, 2003, 00:00

  • PSN20 QUALITY OF LIFE AND PSORIASIS. IMPACT OF TACALCITOL TREATMENT IN SPANISH POPULATION

    Nov 1, 2003, 00:00

  • PHL8 COST-EFFECTIVENESS OF PATHOGEN INACTIVATION VIA THE INTERCEPT BLOOD SYSTEM FOR PLATELETS IN SPAIN

    Nov 1, 2003, 00:00

  • PSN18 PSORIASIS- QUALITY OF LIFE ACCORDING TO GENDER

    Nov 1, 2003, 00:00

  • PUK6 COST-MINIMIZATION ANALYSIS OF TENSIONFREE VAGINAL TAPE VS. OPEN BURCH COLPOSUSPENSION IN FEMALE STRESS URINARY INCONTINENCE

    Nov 1, 2003, 00:00

  • PNM13 ECONOMIC EVALUATION OF DATSCAN IN THE DIAGNOSIS OF PARKINSONISM

    Nov 1, 2003, 00:00

  • PCN9 CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV)-OUTCOMES OF PROPHYLACTIC CARE AND COSTS IN GERMAN CANCER CENTERS

    Nov 1, 2003, 00:00

  • PMH10 COSTS AND EFFECTS OF RISPERDAL CONSTATM IN COMPARISON TO CONVENTIONAL DEPOT AND SHORT-ACTING ATYPICAL FORMULATIONS IN GERMANY

    Nov 1, 2003, 00:00

  • PIN7 AN ANALYSIS OF IN-VITRO UROPATHOGEN SENSITIVITY DATA TO UPDATE THE GUIDELINES FOR THE EMPIRIC TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN ADULT WOMEN IN A MANAGED CARE SETTING

    Nov 1, 2003, 00:00

  • PHL2 PROBABILITY OF INITIATING ERYTHROPOIETIC THERAPY

    Nov 1, 2003, 00:00

  • PMD23 IDENTIFICATION OF UNIT COSTS IN RHEUMATOID ARTHRITIS-RESEARCH APPROACH AND RESULTS

    Nov 1, 2003, 00:00

  • PNM21 PIRIBEDIL IMPROVES QUALITY OF LIFE IN PATIENTS WITH PARKINSONS DISEASE IN RUSSIA

    Nov 1, 2003, 00:00

  • PDB8 AN ANALYSIS OF THE RELATIONSHIP BETWEEN RAPID TRANSITION TO INSULIN, AREA UNDER THE CURVE FOR HBA1C MEASURES ACROSS TIME AND DIABETESRELATED COMPLICATIONS- A GERMANY POPULATION BASED STUDY

    Nov 1, 2003, 00:00

  • PHP3 PERSPECTIVES AND BARRIERS IN THE DEVELOPMENT OF PHARMACOECONOMICS AND ITS APPLICATIONS IN POLANDPRELIMINARY RESULTS OF A SURVEY

    Nov 1, 2003, 00:00

  • PNM15 DO PEOPLE CONSIDER THE EFFECTS OF ILL-HEALTH ON INCOME AND LEISURE WHEN ANSWERING HEALTH-RELATED QUALITYOF-LIFE QUESTIONS?

    Nov 1, 2003, 00:00

  • PCV63 COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES WITHOUT ST-SEGMENT ELEVATION IN THE NETHERLANDS

    Nov 1, 2003, 00:00

  • PCV6 ASSESSMENT OF THE QUALITY OF DRUG TREATMENT IN ESSENTIAL HYPERTENSION IN SLOVAK REPUBLIC

    Nov 1, 2003, 00:00

  • PMH21 PSORIASIS AND DEPRESSIVE SYMPTOMATOLOGY- SPANISH RESULTS

    Nov 1, 2003, 00:00

  • CV3 PROSPECTIVE COHORT STUDY IN HIP FRACTURE- RISK AND ECONOMIC IMPACT OF VENOUS THROMBO-EMBOLIC COMPLICATIONS (VTE) IN REAL LIFE

    Nov 1, 2003, 00:00

  • PAE1 CHRONIC ALLERGIC RHINITIS, ECONOMICS IMPACT- FRENCH SITUATION

    Nov 1, 2003, 00:00

  • PRP13 COSTS OF COPD IN GERMANY-RESULTS OF A COST-OF ILLNESS STUDY

    Nov 1, 2003, 00:00

  • PAR7 PHARMACOECONOMICS OF COX-2-SELECTIVE INHIBITORS VERSUS NON-SELECTIVE NSAIDS AND CONCOMITANT COUMARIN USE- ECONOMIC EVALUATION LINKED TO A CASECONTROL STUDY

    Nov 1, 2003, 00:00

  • PCV11 PREDICTIVE VALUE OF TROPONIN T LEVELS FOR HEART FAILURE AFTER UNSTABLE ANGINA OR NON ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION

    Nov 1, 2003, 00:00

  • PHP9 THE IMPACT OF CHANGING REIMBURSEMENT MECHANISMS- THE CASE OF PROPHYLAXIS IN BELGIAN HOSPITALS

    Nov 1, 2003, 00:00

  • PNM7 A COST-EFFECTIVENESS ANALYSIS OF ELETRIPTAN 40MG AND 80MG VERSUS SUMATRIPTAN 50MG AND 100MG IN THE ACUTE TREATMENT OF MIGRAINE

    Nov 1, 2003, 00:00

  • PHP18 REIMBURSING OFFICE-BASED DRUG MANAGEMENT COSTS- POLICY OPTIONS

    Nov 1, 2003, 00:00

  • PDB1 IMPROVED GLYCAEMIC CONTROL AND LESS HYPOGLYCAEMIA WITH INSULIN GLARGINE COMPARED WITH NPH INSULIN IN PATIENTS WITH TYPE 2 DIABETES LEADS TO FEWER LONG-TERM COMPLICATIONS-RESULTS OF THE DIABETES MELLITUS SIMULATION MODEL

    Nov 1, 2003, 00:00

  • RX2 CHARACTERIZATION OF POLYPHARMACY ISSUES AND SUBSEQUENT INTERVENTION IN A POPULATION OF ELDERLY COMMUNITY-DWELLING INDIVIDUALS

    Nov 1, 2003, 00:00

  • PMD30 MODELLING OF PREVALENCE, COSTS AND OUTCOME OF ACID-RELATED DISORDERS USING CLAIMS DATA

    Nov 1, 2003, 00:00

  • PWH2 EFFECTIVITY AND SAFETY OF ORAL LOWDOSE HORMONAL REPLACEMENT THERAPY (COMBINED ESTRADIOL 1MG AND NORETISTERONE 0.5MG) IN CLIMACTERIC SYMPTOMS ON SPANISH POSTMENOPAUSAL WOMEN

    Nov 1, 2003, 00:00

  • PDB6 PREVALENCE OF RENAL FAILURE IN DIABETES TYPE 2- RESULTS FROM A POPULATION STUDY AND THE BELGIAN ESRD REGISTRY

    Nov 1, 2003, 00:00

  • PCV5 OUTCOME AND PROGNOSTIC VALUE OF TROPONIN T IN PATIENTS WITH UNSTABLE ANGINA OR NON-Q-WAVE MYOCARDIAL INFARCTION

    Nov 1, 2003, 00:00

  • PCV80 EARLY EVOLUTION, DETERMINANTS AND PREDICTIVE POWER OF HEALTH RELATED QUALITY OF LIFE IN A MULTICENTRIC POPULATION OF PATIENTS WITH HEART FAILURE

    Nov 1, 2003, 00:00

  • PCV7 MITRAL REPAIR CAN BE SAFELY PERFORMED IN CASES OF INCREASED COMPLEXITY

    Nov 1, 2003, 00:00

  • PUK12 COMPARISON OF TACROLIMUS WITH CYCLOSPORIN IN KIDNEY TRANSPLANTATION- COST-MINIMISATION AND COSTEFFECTIVENESS ANALYSES

    Nov 1, 2003, 00:00

  • PMD35 A METHODOLOGICAL APPROACH TO ASSESS COST DUE TO DYING IN THE CONTEXT OF DECISION ANALYTIC MODELLING

    Nov 1, 2003, 00:00

  • VV8 CLINICAL INCONTINENCE SCORE RELATES TO HEALTH UTILITY VALUES

    Nov 1, 2003, 00:00

  • PIN20 THE IMPACT OF COST-EFFECTIVENESS OF COUNTRY SPECIFIC APPLICATION-THE CASE OF DROTRECOGIN ALFA (ACTIVATED) IN SEVERE SEPSIS

    Nov 1, 2003, 00:00

  • PMD3 OUTCOMES OF AN INTERVENTION TO IMPROVE HOSPITAL ANTIBIOTIC PRESCRIBING- INTERRUPTED TIME SERIES ANALYSIS WITH SEGMENTED REGRESSION

    Nov 1, 2003, 00:00

  • PGS3 META-ANALYSIS OF PPI-BASED TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER PYLORI

    Nov 1, 2003, 00:00

  • PCN11 COMPARING THE PROVIDER TIME AND COSTS FOR RED BLOOD CELL TRANSFUSIONS IN ANAEMIA MANAGEMENT OF CANCER PATIENTS USING THE ACTIVITY-BASED COSTING (ABC) METHOD IN A FRENCH AND AUSTRIAN SETTING

    Nov 1, 2003, 00:00

  • CE2 HEALTH ECONOMIC ASSESSMENT OF THE ATAC TRIAL COMPARING ANASTROZOLE VERSUS TAMOXIFEN IN ADJUVANT TREATMENT OF POSTMENOPAUSAL HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER

    Nov 1, 2003, 00:00

  • Abstracts Index

    Nov 1, 2003, 00:00

  • CV8 CLINICAL OUTCOMES AND COSTS OF DRUG ELUTING STENTS IN THE CARDIAC CATHERIZATION LAB

    Nov 1, 2003, 00:00

  • PPN3 A UK MULTI-CENTRE TRIAL-BASED COSTUTILITY ANALYSIS OF SURGICAL STABILISATION OF THE SPINE VERSUS INTENSIVE REHABILITATION FOR TREATMENT OF CHRONIC LOW BACK PAIN PATIENTS

    Nov 1, 2003, 00:00

  • PMD19 THE COST-EFFECTIVENESS OF TREATMENT FOR TYPE 1 DIABETES

    Nov 1, 2003, 00:00

  • PGS13 COST OF ILLNESS AND QUALITY OF LIFE OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) PATIENTS IN ITALY

    Nov 1, 2003, 00:00

  • PCV59 ECONOMIC EVALUATION OF LOSARTAN COMPARED WITH ATENOLOL IN THE TREATMENT OF HYPERTENSION WITH LEFT VENTRICULAR HYPERTROPHY- COSTMINIMIZATION ANALYSIS BASED ON LIFE STUDY

    Nov 1, 2003, 00:00

  • PCV37 THE ADDITIONAL TREATMENT OF PATIENTS WITH CHRONIC HEART FAILURE WITH METOPROLOL CR/XL WILL LEAD TO COST SAVINGS IN THE GERMAN HEALTH CARE SYSTEM

    Nov 1, 2003, 00:00

  • PRP10 A RANDOMIZED STUDY COMPARING THREE HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRES IN ASTHMATIC PATIENTS

    Nov 1, 2003, 00:00

  • PRP12 AST-PQ16-A NEW QUESTIONNAIRE FOR MEASURING QUALITY OF LIFE (QOL) OF PARENTS OF CHILDREN WITH ASTHMA

    Nov 1, 2003, 00:00

  • PDB3 CLAIMS DATA MEASUREMENTS OF MEDICATION ADHERENCE AND METABOLIC OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES (DM2)

    Nov 1, 2003, 00:00

  • PMD29 A MULTI-OUTCOME DECISION MODEL FOR PARKINSONS DISEASE

    Nov 1, 2003, 00:00

  • PPN2 TOPIRAMATE IS EFFECTIVE IN PATIENTS WITH PERIPHERAL DIABETIC NEUROPATHY FOR WHOM OTHER ANTICONVULSANTS HAVE FAILED

    Nov 1, 2003, 00:00

  • PSN8 COST-OF-ILLNESS STUDY IN PATIENTS SUFFERING FROM CHRONIC PLAQUE PSORIASIS IN GERMANY

    Nov 1, 2003, 00:00

  • PMH12 ECONOMIC CONSEQUENCES OF THE ADVERSE EVENTS RELATED WITH CURRENT ANTIPSYCHOTICS

    Nov 1, 2003, 00:00

  • PDB14 COST-EFFECTIVENESS ANALYSIS OF THE ACARBOSE PHARMACOLOGICAL TREATMENT AS A PREVENTIVE MEASURE OF THE DEVELOPMENT OF TYPE 2 DIABETES IN SUBJECTS DIAGNOSED OF IMPAIRED GLUCOSE TOLERANCE (IGT)

    Nov 1, 2003, 00:00

  • GD2 A COST CONSEQUENCE ANALYSIS OF A NEW ENDOSCOPIC, INJECTABLE TREATMENT AND EXISTING INTERVENTIONS IN GASTRO-OESOPHAGEAL REFLUX DISEASE

    Nov 1, 2003, 00:00

  • PCV26 COST-EFFECTIVENESS OF EXTENDING PROPHYLAXIS WITH FONDAPARINUX IN PREVENTING VENOUS THROMBOEMBOLISM FOLLOWING HIP FRACTURE SURGERY

    Nov 1, 2003, 00:00

  • QL7 PREVALENCE AND QUALITY OF LIFE OF PATIENTS SUFFERING FROM RESTLESS LEGS SYNDROME IN FRANCE-INSTANT STUDY

    Nov 1, 2003, 00:00

  • PCV71 AN ECONOMIC EVALUATION OF TREATMENTS FOR ACUTE MI IN GREECE IN ELDERLY AND LATE TREATMENT PATIENTS

    Nov 1, 2003, 00:00

  • PIN37 INTRODUCTION OF A NEW HEALTH TECHNOLOGY, POTENTIAL BEHAVIOURAL AND ORGANISATIONAL CHANGES AND POLICY IMPACT-ASSESSMENT OF NEW INFLUENZA TREATMENTS

    Nov 1, 2003, 00:00

  • PCV68 A SYSTEMATIC REVIEW OF COSTEFFECTIVENESS OF STATINS IN CARDIOVASCULAR RISK MANAGEMENT

    Nov 1, 2003, 00:00

  • PHP4 ARE THE RESULTS OF ECONOMIC EVALUATIONS GENERALIZABLE? EVIDENCE FROM STUDIES OF PHARMACEUTICALS IN WESTERN EUROPE

    Nov 1, 2003, 00:00

  • PGS1 AN EVIDENCE-BASED APPROACH PROVIDES A QUANTITATIVE ASSESSMENT OF THE EFFICACY OF ESOMEPRAZOLE FOR HEALING OF EROSIVE ESOPHAGITIS BASED ON DISEASE SEVERITY

    Nov 1, 2003, 00:00

  • PHP14 DRUG PRICE INDICES 1980-2002 IN FINLAND

    Nov 1, 2003, 00:00

  • PAE3 RESEARCH 5771- THE ECONOMIC AND QUALITY OF LIFE IMPACT OF SEASONAL ALLERGIC CONJUNCTIVITIS IN OXFORDSHIRE, ENGLAND

    Nov 1, 2003, 00:00

  • PIN27 COST-EFFECTIVENESS AND VALUE OF INFORMATION ANALYSES OF THE USE OF ANTIVIRALS FOR THE TREATMENT OF INFLUENZA IN HEALTHY ADULTS

    Nov 1, 2003, 00:00

  • PCV79 DEVELOPMENT AND VALIDATION OF THE NEW HEALTH-RELATED QUALITY OF LIFE INSTRUMENT SPECIFIC TO PATIENTS WITH CORONARY ARTERY DISEASE (CAD) IN POLAND- POL-CAD

    Nov 1, 2003, 00:00

  • PMD10 GENETIC TESTING, PREDICTIVE GENETIC TESTING FOR HEREDITARY CANCER

    Nov 1, 2003, 00:00

  • PNM12 EARLY DECISION MAKING MODELLING IN PARKINSONS DISEASE

    Nov 1, 2003, 00:00

  • VV4 DEVELOPING A PREFERENCE-BASED MEASURE FOR POSTMENOPAUSAL HEALTH

    Nov 1, 2003, 00:00

  • PIN39 DIRECT COST ANALYSIS OF HEPATITIS B INFECTION IN FRANCE

    Nov 1, 2003, 00:00

  • PWH3 PULSED OESTROGEN THERAPY WITH INTRANASAL 17-B OESTRADIOL IMPROVES WOMENS QUALITY OF LIFE IN THE EARLY POSTMENOPAUSAL PERIOD

    Nov 1, 2003, 00:00

  • PCV3 EFFECTIVENESS OF LIPID-LOWERING THERAPY IN PRIMARY CARE IN FRANCE

    Nov 1, 2003, 00:00

  • PMH24 EARLY SUSTAINED REMISSION IN PATIENTREPORTED OUTCOMES AMONG PRIMARY CARE PATIENTS WITH MAJOR DEPRESSIVE DISORDER

    Nov 1, 2003, 00:00

  • PUK5 COMPARISON OF THE DOSE AND COST OF EPREX BY ROUTE OF ADMINISTRATION

    Nov 1, 2003, 00:00

  • PMD9 OPTIMIZATION OF AIDS PILOT CLINICAL TRIAL USING LEAMSIM

    Nov 1, 2003, 00:00

  • PCV2 NEW TECHNOLOGIES IN THE US MEDICARE- AN EXAMINATION OF STENT ADOPTION

    Nov 1, 2003, 00:00

  • PGS4 ESOMEPRAZOLE AS MAINTENANCE THERAPY IN EROSIVE ESOPHAGITIS- A QUANTITATIVE ASSESSMENT OF EFFICACY USING AN EVIDENCE-BASED APPROACH

    Nov 1, 2003, 00:00

  • HP2 THE IMPACT OF TREATMENT MANAGEMENT ALGORITHMS AND EVALUATED TIME HORIZON ON ANTIVIRAL TREATMENT COSTS IN CHRONIC HEPATITIS C

    Nov 1, 2003, 00:00

  • PIN6 INDICATORS OF ANTIBIOTIC USE IN PRIMARY HEALTH CARE OF REPUBLIC OF SRPSKA

    Nov 1, 2003, 00:00

  • PCN2 BREAST CANCER PATIENTS USE OF HEALTH CARE INFORMATION IN DECISION-MAKING AND IN COPING WITH ILLNESS- RESULTS OF A QUALITATIVE STUDY

    Nov 1, 2003, 00:00

  • PAE2 THE BURDEN OF ALLERGIC CONJUNCTIVITIS IN THE UK- FINDINGS FROM A RETROSPECTIVE REVIEW OF THE GPRD DATABASE 1990-2000

    Nov 1, 2003, 00:00

  • PCN17 COST REDUCTION IN THE DIAGNOSTIC EVALUATION OF PATIENTS WITH NON-SMALL CELL LUNG CANCER USING ENDOSCOPIC ULTRASONOGRAPHY WITH FINE-NEEDLE ASPIRATION

    Nov 1, 2003, 00:00

  • PHP7 PHARMACOECONOMICS IN HEALTH CAREDECISION MAKING- A SURVEY ON CHINA HEALTH CARE SYSTEM

    Nov 1, 2003, 00:00

  • PCV51 IRBESARTAN IS COST-SAVING COMPARED TO AMLODIPINE AND STANDARD BLOOD PRESSURE TREATMENT IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN HUNGARY

    Nov 1, 2003, 00:00

  • PCV4 PREVENTION OF DEEP-VEIN THROMBOSIS AFTER TOTAL KNEE ARTHROPLASTY IN ASIAN PATIENTS- COMPARISON OF PROPHYLAXIS WITH LOW MOLECULAR WEIGHT HEPARIN AND INDOMETHACIN

    Nov 1, 2003, 00:00

  • PHP12 3THE ECONOMIC IMPLICATIONS OF NONCOMPLIANCE AFTER RENAL TRANSPLANTATION

    Nov 1, 2003, 00:00

  • PIN15 COST-EFFECTIVENESS ANALYSIS OF VORICONAZOLE VERSUS AMPHOTERICIN B IN THE TREATMENT OF INVASIVE ASPERGILLOSIS IN SPAIN

    Nov 1, 2003, 00:00

  • PWH4 VASOMOTOR SYMPTOMS AND QUALITY OF LIFE (QOL) IN POSTMENOPAUSAL WOMEN

    Nov 1, 2003, 00:00

  • PSN17 PSORIASIS AND QUALITY OF LIFE SPANISH RESULTS

    Nov 1, 2003, 00:00

  • PSN12 QUALITY-OF-LIFE IN PATIENTS SUFFERING FROM ATOPIC DERMATITIS IN GERMANY

    Nov 1, 2003, 00:00

  • PIN14 POST-EXPOSURE INFLUENZA PROPHYLAXIS WITH OSELTAMIVIR- COST-EFFECTIVENESS AND COST-UTILITY IN FAMILIES IN THE UK

    Nov 1, 2003, 00:00

  • PDB4 POPULATION-BASED DIABETES INTERVENTION IN A MANAGED CARE SETTING

    Nov 1, 2003, 00:00

  • CE4 COST-EFFECTIVENESS OF CAPECITABINE IN COMBINATION WITH DOCETAXEL VERSUS DOCETAXEL MONOTHERAPY IN PATIENTS WITH ADVANCED AND/OR METASTATIC BREAST CANCER IN FRANCE

    Nov 1, 2003, 00:00

  • PIN30 COSTS OF PULMONARY TUBERCULOSIS IN UKRAINE

    Nov 1, 2003, 00:00

  • PAR15 THE BURDEN OF OSTEOPOROSIS IN EUROPE- AN EPIDEMIOLOGICAL MODEL

    Nov 1, 2003, 00:00

  • PHP26 INTENSIVIST PRACTICE CHANGE IN GLUCOSE CONTROL FOR CRITICALLY ILL PATIENTS

    Nov 1, 2003, 00:00

  • PCN1 AN ASSESSMENT OF THE UPDATED RESULTS FROM THE ARIMIDEX, TAMOXIFEN, ALONE OR IN COMBINATION (ATAC) TRIAL- AN EVIDENCE-BASED MEDICINE APPROACH

    Nov 1, 2003, 00:00

  • PCN3 EXPERT PANEL DEPICTION OF CLINICAL PRACTICE IN THE TREATMENT OF BREAST CANCER PATIENTS IN GREECE

    Nov 1, 2003, 00:00

  • PIN11 ABACAVIR HYPERSENSITIVITY- IS PREPRESCRIPTION GENOTYPING COSTEFFECTIVE?

    Nov 1, 2003, 00:00

  • PAR11 IMPLEMENTATION STUDY OF A HEALTH EDUCATION AND EXERCISE PROGRAM FOR OSTEOARTHRITIS OF THE KNEE

    Nov 1, 2003, 00:00

  • PIN35 MENINGOCOCCAL C VACCINATION OF CHILDREN AGED LESS THAN 1 YEAR- INCLUSION OF HERD IMMUNITY LEADS TO LESS FAVORABLE COST-EFFECTIVENESS RATIOS

    Nov 1, 2003, 00:00

  • MS3 A DEMONSTRATION OF THE USE OF BAYESIAN DECISION THEORY TO OPTIMISE DRUG DEVELOPMENT PROGRAMMES

    Nov 1, 2003, 00:00

  • PUK7 DITROPAN XL VERSUS DETROL IN CANADA- ECONOMIC ANALYSIS

    Nov 1, 2003, 00:00

  • PAE5 PREVALENCE OF LOW VISION AND BLINDNESS IN FRANCE

    Nov 1, 2003, 00:00

  • PNM2 COST-EFFECTIVENESS OF ELETRIPTAN 40MG COMPARED WITH STANDARD DOSES OF AVAILABLE TRIPTANS FOR ACUTE MIGRAINE ATTACKS IN SPAIN

    Nov 1, 2003, 00:00

  • PSN11 THE WILLINGNESS-TO-PAY FOR PSORIASIS TREATMENT IN DENMARK

    Nov 1, 2003, 00:00

  • RX3 THE ANTIBIOTIC USE IN POLAND IN THE TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADOLESCENTS AND ADULTS VERSUS CURRENT GUIDELINES

    Nov 1, 2003, 00:00

  • PHP15 COMPARISON OF MARKET EXCLUSIVITY OF PHARMACEUTICALS IN CANADA, THE UNITED STATES, THE UNITED KINGDOM AND FRANCE

    Nov 1, 2003, 00:00

  • MH2 COST-EFFECTIVENESS OF THE HIT PROGRAMME IN PATIENTS WITH SCHIZOPHRENIA AND PERSISTENT AUDITORY HALLUCINATIONS

    Nov 1, 2003, 00:00

  • CV1 A COST-BENEFIT MODEL FOR PERINDOPRIL IN SECONDARY STROKE PREVENTION

    Nov 1, 2003, 00:00

  • CV5 SHORT AND LONG TERM COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME WITHOUT S T-SEGMENT ELEVATION (ACS) IN SCANDINAVIAN COUNTRIES

    Nov 1, 2003, 00:00

  • PCV77 THE ECONOMIC ASSESSMENT OF LIPID LOWERING THERAPY WITH EZETIMIBE IN SPAIN

    Nov 1, 2003, 00:00

  • PMH1 METHYLPHENIDATE FORMULATION IS ASSOCIATED WITH ACCIDENT/INJURY RATE IN CHILDREN WITH ADHD

    Nov 1, 2003, 00:00

  • PAR10 CROSS-CULTURAL ADAPTATION AND VALIDATION OF KOREAN VERSION OF EQ-5D IN PATIENTS WITH RHEUMATIC DISEASES

    Nov 1, 2003, 00:00

  • PAE13 COST-EFFECTIVENESS ANALYSIS OF TIMOLOL LATANOPROST AND TRAVOPROST IN 3 EUROPEAN COUNTRIES- THE UK, GERMANY AND FRANCE

    Nov 1, 2003, 00:00

  • PRP4 COST-UTILITY OF BECLOMETHASONEEXTRAFINE (BDP-EF) IN PATIENTS WITH MODERATE AND SEVERE ASTHMA

    Nov 1, 2003, 00:00

  • VV2 DESIGN AND VALIDATION OF A NEW WEB-BASED STANDARD GAMBLE INTERVIEW

    Nov 1, 2003, 00:00

  • PHP23 THE DRUG PRICE REFERENCE INDEX STUDY OF THE PHILIPPINE HEALTH INSURANCE CORPORATION

    Nov 1, 2003, 00:00

  • PNM4 COST-EFFECTIVENESS STUDY OF RIZATRIPTAN VS. USUAL CARE IN THE TREATMENT OF MIGRAINE IN CANADA

    Nov 1, 2003, 00:00

  • PCV61 THE COST-EFFECTIVENESS OF EXTENDED VENOUS THROMBOEMBOLISM PROPHYLAXIS WITH ENOXAPARIN VERSUS SHORT-TERM PROPHYLAXIS AFTER ELECTIVE HIP REPLACEMENT IN POLAND

    Nov 1, 2003, 00:00

  • PAR5 THE TOTAL COSTS OF TREATMENT WITH VALDECOXIB COMPARED TO GENERIC DICLOFENAC ARE SIMILAR IN PATIENTS WITH RHEUMATOID ARTHRITIS IN GERMANY

    Nov 1, 2003, 00:00

  • VV6 TRANSFORMING THE UNIFIED PARKINSONS DISEASE RATING SCALE INTO A UTILITY SCALE

    Nov 1, 2003, 00:00

  • PCN16 HEAD AND NECK CANCER COSTS IN A FRENCH PRIVATE CENTRE

    Nov 1, 2003, 00:00

  • PCV18 HEALTH SYSTEM COSTS OF OUT-OF-HOSPITAL CARDIAC ARREST IN RELATION TO TIME TO SHOCK

    Nov 1, 2003, 00:00

  • PCV46 SWITCHING PATIENTS TO ROSUVASTATIN FROM ATORVASTATIN OR OTHER STATINS IS COST-EFFECTIVE- PHARMACOECONOMIC ANALYSIS OF MERCURY I

    Nov 1, 2003, 00:00

  • PSN19 DERMATOSIS AND DEPRESSIVE SYMPTOMATOLOGY- FRENCH RESULTS

    Nov 1, 2003, 00:00

  • PCN6 HEALTH ECONOMIC EVALUATION OF A NEW CONTRAST PRODUCT FOR LIVER MRI IN COLORECTAL CANCER PATIENTS

    Nov 1, 2003, 00:00

  • PMD36 ARE ISPOR SHORT COURSES A COSTEFFECTIVE WAY OF EDUCATING PARTICIPANTS AND ENHANCING MEETING ATTENDANCE?

    Nov 1, 2003, 00:00

  • CP1 LOWER PERSISTENCE WITH ANTIHYPERTENSIVE DRUGS AMONG WOMEN COMPARED TO MEN

    Nov 1, 2003, 00:00

  • PCV39 ECONOMIC EVALUATION OF THE MEDENOX (PROPHYLAXIS IN MEDICAL PATIENTS WITH ENOXAPARIN) TRIAL FROM THE PERSPECTIVE OF HOSPITALS IN GERMANY- RESULTS OF A SUBGROUP ANALYSIS

    Nov 1, 2003, 00:00

  • CS4 COST-BENEFIT ANALYSIS OF AN INTERNET-BASED PATIENT EDUCATION PROGRAMME FOR ASTHMATIC CHILDREN AND ADOLESCENTS

    Nov 1, 2003, 00:00
  • «
  • 171
  • 172
  • 173 (current)
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • »